Anavex Life Sciences Corp (AVXL)

[JB3729]

Fidelity news feed -

Anavex Life Sciences Corp Jumps 5% on Positive Data on ANAVEX 2-73 in Rett Syndrome

MIDNIGHT TRADER 2:03 PM ET 2/25/2016
Symbol Last Price Change
AVXL 4.433down +0.193 (+4.55%)
QUOTES AS OF 03:02:58 PM ET 02/25/2016

03:03 PM EST, 02/25/2016 (MT Newswires) -- Anavex Life Sciences Corp(AVXL) shares were higher nearly 5% on Thursday after announcing positive data on ANAVEX 2-73 in an exploratory study in a Rett syndrome model at the 2016 Epilepsy Pipeline Conference.

"The data demonstrates dose related and significant improvements in an array of behavioral and gait paradigms in a mouse model with a MECP2-null mutation that causes neurological symptoms that mimic Rett syndrome. There is a tremendous need for therapeutic solutions for the individuals living with Rett syndrome and their families, and we are very encouraged by the data we have seen with ANAVEX 2-73," chief science officer Steven Kaminsky said in a statement.

Anavex shares traded in the lower half of their 52-week range of $0.68 - $14.84.

Price: 4.45, Change: +0.21, Percent Change: +4.83

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.